4.7 Meeting Abstract

Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma.

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 16, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

-

Categories

Funding

  1. Merck Co.

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available